Stepan Company (SCL) 16th Annual Midwest Ideas Conference summary
Event summary combining transcript, slides, and related documents.
16th Annual Midwest Ideas Conference summary
23 Nov, 2025Strategic focus and growth markets
Emphasis on priority growth markets with strategic tailwinds, including agriculture, oil-fed chemicals, construction, personal care, and insulation products.
Expansion of customer base, especially tier two and three customers, across all end markets.
Significant investments in new facilities, notably the Pasadena, Texas alcoxylation plant, to support future growth.
Global manufacturing footprint with 60% of sales in North America, followed by Europe and other regions.
Focus on operational excellence and cost optimization across the network.
Business segments and market drivers
Operates in three segments: Surfactants (largest), Polymers (second largest), and Specialty Products (niche focus).
Surfactants serve six key end markets, including agriculture, oil, construction, personal care, cleaning, and laundry.
Polymers business driven by demand for insulation and regulatory requirements, especially in the EU.
Specialty Products cater to beverages, energy drinks, and baby formula, leveraging advanced R&D.
Growth in agriculture and oil-fed surfactants, and rigid polymers, with double-digit increases in early 2024.
Innovation, R&D, and customer expansion
Over 230 chemists and 14 application centers globally, with 33 new products launched in 2024 (10% of revenue).
Customer-centric innovation includes technical service, formulation expertise, and process technology.
Added 1,800 new surfactant customers in the past year, with a sustained trend of customer base expansion.
Focus on value-added services for smaller customers, with 22,000 potential new and existing customers identified.
Continuous trend of adding 400+ new customers per quarter in 2024.
Latest events from Stepan Company
- Adjusted EBITDA fell 14% as restructuring charges drove a net loss, but free cash flow improved.SCL
Q1 202628 Apr 2026 - 2025 results highlight diversified growth, operational excellence, and a robust innovation pipeline.SCL
Investor presentation28 Apr 2026 - EBITDA grew 6% in 2025; Project Catalyst to drive $100M savings, with H2 2026 margin recovery.SCL
Q4 202511 Apr 2026 - Proxy covers director elections, pay practices, auditor ratification, and strong governance.SCL
Proxy filing25 Mar 2026 - Adjusted EBITDA grew 4% in Q2 2024 despite lower net income and significant one-time expenses.SCL
Q2 20242 Feb 2026 - Q3 net income up 88% to $23.6M, EBITDA up 11%, with strong Surfactants and cost savings.SCL
Q3 202417 Jan 2026 - Net income up 42% and EBITDA up 12% on strong surfactant and specialty growth.SCL
Q1 202524 Dec 2025 - Net income up 25% and adjusted EBITDA rose 4%, with Pasadena facility to boost 2025 growth.SCL
Q4 202423 Dec 2025 - Key votes include director elections, executive pay, auditor ratification, and equity plan expansion.SCL
Proxy Filing1 Dec 2025